OX40L Inhibition Suppresses KLH‐driven Immune Responses in Healthy Volunteers: A Randomized Controlled Trial Demonstrating Proof‐of‐Pharmacology for KY1005-Reference-Cited by-同舟云学术

OX40L Inhibition Suppresses KLH‐driven Immune Responses in Healthy Volunteers: A Randomized Controlled Trial Demonstrating Proof‐of‐Pharmacology for KY1005

Published:2022-03 Issue:5 Volume:111 Page:1121-1132
ISSN:0009-9236
Container-title:Clinical Pharmacology & Therapeutics
language:en
Short-container-title:Clin Pharma and Therapeutics

Author:

Saghari Mahdi¹²,Gal Pim¹²,Gilbert Sally³,Yateman Martin³,Porter‐Brown Ben³,Brennan Nuala³,Quaratino Sonia³,Wilson Rosamund³,Grievink Hendrika W.¹⁴,Klaassen Erica S.¹,Bergmann Kirsten R.¹,Burggraaf Jacobus¹²⁴,Doorn Martijn B. A.¹⁵,Powell John³,Moerland Matthijs¹²,Rissmann Robert¹²⁴

Affiliation:

1. Centre for Human Drug Research Leiden The Netherlands

2. Leiden University Medical Centre Leiden The Netherlands

3. Kymab Ltd. Cambridge UK

4. Leiden Academic Centre for Drug Research Leiden The Netherlands

5. Department of Dermatology Erasmus Medical Centre Rotterdam The Netherlands

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cpt.2539